Long-term alpha-adrenergic-blocking therapy in detrusor-urethra dyssynergia

Neurogenic dyssynergia was treated with alpha-adrenergic blockers. Only 21 of 43 highly selected patients with residual urines and low flow rates continued therapy with phenoxybenzamine for more than 6 months, despite initial benefits. The causes of therapy discontinuation are discussed. A combination of 5 mg dibenzylin, 3 times daily, with parasympathomimetic drugs is often necessary. The mechanisms of action of alpha-adrenergic-blocking agents are discussed.